X

Trial Profile

Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Dexamethasone
Indications CNS cancer; Diffuse large B cell lymphoma; Intraocular lymphoma; Lymphoma
Focus Proof of concept; Therapeutic Use
Acronyms REVRI

Most Recent Events

09 Jul 2019 Status changed from active, no longer recruiting to completed.
04 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
29 Jan 2019 Results published in the Annals of Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com